SHORT ANSWERS
Retatrutide questions answered with study facts.
Each answer names who was studied, what doctors found, and what remains unknown.
Did retatrutide lower liver fat?
A 48-week study followed 98 people who had obesity plus fatty liver disease. With 12 mg, liver fat fell 82.4% by week 24. A scan measured the fat. Eighty-six percent reached a normal amount below 5%. By week 48, the fall was 86.0% with 12 mg [5]. No other Phase 2 drug study had published a larger drop. This was an early test of benefit and harm.
Ask your doctor what your own liver scan shows.
Retatrutide changed hunger, insulin, and liver fat
Retatrutide copies three hormones made by the body. One, called GLP-1, curbs hunger and slows the stomach. The next hormone helps release insulin. The third helps use stored energy and liver fat. Studies found larger changes than older one-part or two-part drugs. A 2025 review found weight loss up to 24% at 48 weeks [6]. That can't predict your result.
Your body may not match a study average.
Cell tests found three retatrutide effects
Retatrutide is one lab-made drug. It copies three hormones that give orders to cells. Tests in cells confirmed all three jobs [3]. The first curbs hunger. The second helps release insulin. The third increases energy use. In a 48-week Phase 2 study, 12 mg each week brought a 24.2% weight fall. Placebo, a shot without retatrutide, brought a 2.1% fall [1]. The full how does retatrutide work page gives more detail.
You can understand the jobs without the lab codes.
How to reconstitute retatrutide has no approved guide
No official guide tells people how to mix retatrutide. Study doctors used a pre-filled pen. They didn't mix a dry powder with water. The FDA and maker haven't set a standard for research bottles. Online guides come from personal practice. They don't describe a checked drug process.
An online post can't tell what your bottle holds.
Retatrutide is not FDA approved
The FDA hadn't approved retatrutide by mid-2026. No other drug agency had approved it. Eli Lilly was running Phase 3 studies. Those larger studies cover obesity, type 2 diabetes, the heart, and kidneys. The company hadn't filed a new drug request. Semaglutide and tirzepatide are approved. Retatrutide isn't.
Your pharmacist can't fill an unapproved retatrutide order.
No retatrutide sale date has been announced
No approved sale date exists. Phase 3 studies are still running. The company must first send its results to the FDA. If the FDA accepts the filing, a standard review takes 10-12 months. The company hasn't announced a filing. Forum dates aren't confirmed company dates.
Check later news against an FDA notice.
Retatrutide has no home-use directions
The published work reports study care, not home steps. In Phase 2 studies, doctors gave a weekly shot into the fatty layer. They started low, then increased the amount. The slow rise helped with stomach trouble. A doctor watched each person. Retatrutide isn't prescribed outside a study.
Your doctor can't turn that study plan into regular care.
Retatrutide changes began during the first weeks
Study scales showed changes within the first 4-12 weeks. Weight kept falling through the 48-week Phase 2 study. In the first small study, the top group lost 8.96 kg more than placebo over 12 weeks [4]. Liver fat fell by 24 weeks. It kept falling through 48 weeks [5]. The drug remains in blood for a 6-day span. With weekly shots, the blood amount levels off after roughly 3-4 weeks.
You may feel less hunger before the scale moves.
No study proves retatrutide beats tirzepatide
No Phase 2 study tested the drugs face to face. No other Phase 2 result can answer that question. Separate studies report a 24.2% weight fall for retatrutide. One review found an 81% liver-fat drop after allowing for placebo. Tirzepatide had 47%. Semaglutide had 41% [7]. Eli Lilly has begun a Phase 3 study with both drugs. Results aren't out.
You can't pick a winner from separate studies.
Weekly retatrutide amounts came from watched studies
Two Phase 2 obesity studies used 1, 4, 8, and 12 mg each week. A diabetes study used steps from 0.5 to 12 mg. Phase 2 study doctors watched each person. They could change an amount [1][2]. These aren't home-use directions. Retatrutide has no approved dose. Doctors and pharmacists can't prescribe it outside trials.
Those study amounts don't become your dose.
Retatrutide trials did not use germ-killing mixing water
Published studies didn't use dry retatrutide powder. They used a pre-filled pen. No checked steps exist for mixing research bottles. Forum methods borrow steps used with other lab drugs. Those steps haven't been proved right for the liquid used in retatrutide studies. No approved source gives mixing steps.
You can't see germs or strength in dry powder.
No study explains how to switch to retatrutide
No published study tells doctors how to switch these two drugs. Tirzepatide is approved. Retatrutide isn't. Doctors can't guide a normal switch to a drug found only in trials. Reviews may compare separate studies. They can't serve as a switching guide.
Your doctor has no approved retatrutide switch to offer.
Retatrutide is not a hormone called GLP-3
Retatrutide doesn't copy a hormone called GLP-3. No such hormone job exists. The drug copies GLP-1 and two other known hormones. They affect hunger, insulin, energy use, and liver fat. GLP-3 isn't the third hormone. The first is called GLP-1, a gut hormone released after meals. Scientists call retatrutide a three-part drug. The name GLP-3 came from public talk, not medicine [3].
If you hear that label, the name itself is wrong.
Only active studies offer retatrutide with medical care
Retatrutide isn't approved. No prescription sale exists. Lawful access means joining an active trial. A research market does exist. In 2025, the FDA mailed sellers over 50 warning letters. Those bottles aren't checked like approved drugs. Their contents and cleanliness may be wrong. No clinic watches their use.
A trial listing can show whether it is taking people.
Retatrutide is being tested for several health problems
Studies cover obesity, type 2 diabetes, and fatty liver disease. They also watch for heart and kidney harm. Retatrutide has no approved use. Phase 2 studies found weight falls up to 24.2%. A long-term sugar test fell up to 2.02%. Liver fat fell up to 82.4% [1][2][5]. A 2025 review asked how the three hormone jobs may work together [6].
Your health problem doesn't make retatrutide approved care.
Retatrutide copies three hormones made by the body
Retatrutide copies three hormones. One comes from the gut and curbs hunger. Doctors call it GLP-1. A second gut hormone helps release insulin after meals. The third comes from the pancreas and helps use stored energy. Tests compared retatrutide with GLP-1 and the other hormones [3]. Researchers also measured how much drug each job needed. Those tests can't settle long-term safety.
Keep the three jobs in mind, not the lab codes.
Trials may study retatrutide, but stores cannot sell it
Retatrutide is an investigational new drug. It is legal to study in authorized clinical trials. It is legal for Eli Lilly to manufacture and distribute for trial purposes under IND authorization. It is not legal to market or sell as a drug without FDA approval, which it does not have. The FDA's issuance of more than 50 warning letters to vendors in 2025 reflects enforcement actions against gray-market retatrutide sales. Research-labeled compounds occupy a complex regulatory zone — not explicitly scheduled as controlled substances, but not lawfully marketed as drugs.
The structural difference between those channels is supervision. Inside a trial, every retatrutide dose is administered under investigator oversight with a protocol behind it. For prescription-only care at mypromise.com, Promise Peptides currently prescribes compounded tirzepatide after a licensed U.S. clinician examines the individual case and decides whether to prescribe. Retatrutide is excluded from that service. An assessment can end without a prescription. Patients must be in the U.S.; the options differ according to both the state and the treatment. This compounded product has no FDA approval, whereas FDA-approved tirzepatide exists. Bottles labelled for research are still sold, without that layer of clinical supervision. Retatrutide remains investigational; it has no route to a routine telehealth prescription.
Retatrutide studies used one shot each week
All Phase 2 studies gave a shot beneath the skin each week. The first small study found retatrutide in blood for a 6-day span. That finding supports a 7-day gap [4]. Study amounts ran from 1 to 12 mg. These facts tell you what researchers did. They don't tell you what to take.
Weekly timing describes the studies, not your care.
Retatrutide blood levels took weeks to level off
The first small study found about 6 days. It included 72 adults with type 2 diabetes [4]. An added part binds retatrutide to a blood protein. The bond slows the drug's exit. With weekly shots, the amount in blood takes about 3-4 weeks to level off. That explains the study timing.
Your doctor may call this the drug's half life.
Retatrutide has no approved storage steps
Retatrutide has no approved drug label. Therefore, no approved label gives storage steps outside a trial. Each study clinic stored its supply under study rules. Full details weren't made public. Research bottles don't carry storage proof from checked drug tests.
A colder shelf can't replace missing proof.
Retatrutide and semaglutide are different drugs
Semaglutide is available in FDA-approved prescription products. It copies one gut hormone, called GLP-1, that curbs hunger. Retatrutide copies that hormone plus two others. Semaglutide has FDA approval for type 2 diabetes and long-term weight care. Retatrutide isn't approved. The drugs can't be swapped as though they were the same.
A semaglutide prescription does not provide retatrutide.
No study proves retatrutide beats semaglutide
No face-to-face study has been published. Separate studies report a 24.2% weight fall with retatrutide at 48 weeks. A semaglutide study found 14.9% at 68 weeks with 2.4 mg. A review found an 81% liver-fat drop for retatrutide. Semaglutide had 41% [7]. These aren't head-to-head results. Semaglutide has years of safety use. Its larger Phase 3 studies are complete. GLP-1 safety has longer follow-up. Retatrutide has only Phase 2 safety findings so far. Another Phase 2 test is not long-term proof.
You can compare figures while keeping that limit.